In 2011, Boehringer Ingelheim achieved net sales of about $17.1 billion ( 13.2 billion euro). R&D expenditure in the business area Prescription Medicines corresponds to 23.5% of its net sales.For more information, please visit http://us.boehringer-ingelheim.com and follow us on Twitter at http://twitter.com/boehringerus.
RE-LY® Sub-Analysis Suggests Similar Safety And Efficacy With Pradaxa® (dabigatran Etexilate Mesylate) Versus Warfarin In NVAF Patients With And Without Diabetes
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts